tbuckley/cabot-search huggingface dataset:
The prevalence of hypovitaminosis C
Authors: E. Cheraskin
Journal: JAMA (1985)

<h3>To the Editor.—</h3> I wish to respond to the magnificent report by Reuler et al<sup>1</sup>in which they point out the protean nature of adult scurvy and raise the question as to the real incidence and prevalence of hypovitaminosis C. I should like to provide two specific pieces of data. First, Schorah<sup>2</sup>reviewed the literature on this very subject (Table) and concluded that somewhere between 3% of young and healthy subjects and 100% of the institutionalized young suffer from hypovitaminosis C and 0% (healthy young subjects) to 50% (institutionalized elderly) may possibly demonstrate classic scurvy. In our clinic we have examined the epidemiology of vitamin C in four unique populations with over 4,000 subjects including the following: (1) a dental school patient population,<sup>3</sup>(2) patients in a dental prepayment program,<sup>4</sup>(3) orthodontic patients,<sup>5,6</sup>and (4) a selected group of Floridian dentists and their staffs.<sup>7,8</sup>Depending
Malpractice reform
Authors: G. Dunea
Journal: BMJ (1995)

Background: In patients with melanoma, early dissemination via lymphatic and hematogenous routes is frequently seen. Thus, besides clinical follow-up examination and imaging, reliable melanoma-specific serological tumor markers are needed. Patients and Methods: We retrospectively compared two serum markers for melanoma, S100 and melanoma-inhibitory activity (MIA), for monitoring of patients with metastatic melanoma under either adjuvant or therapeutic vaccination immunotherapy with dendritic cells (DC). Serum was obtained from a total of 100 patients (28 patients in stage III and 72 patients in stage IV, according to the American Joint Committee on Cancer 2002) at regular intervals during therapy, accompanied by follow-up imaging. Results: When relapse was detected, both markers often remained within normal range. In contrast, in patients with metastatic measurable disease receiving therapeutic and not adjuvant DC vaccination, an increase of both markers was a strong indicator for disease progression. When comparing both markers in the whole study population, MIA showed a superior sensitivity to detect disease progression. Conclusion: S100 and MIA are highly sensitive tumor markers for monitoring of patients with melanoma with current metastases, but less sensitive for monitoring of tumor-free patients. In the current study, MIA had a slightly superior sensitivity to detect progressive disease compared to S100 and seems to be more useful in monitoring of patients with metastatic melanoma receiving immunotherapy.
BOOKS RECEIVED
Journal: British Journal of Dermatology (1933)

British Journal of DermatologyVolume 45, Issue 8-9 p. 384-384 BOOKS RECEIVED First published: August 1933 https://doi.org/10.1111/j.1365-2133.1933.tb10198.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume45, Issue8-9August 1933Pages 384-384 RelatedInformation
Tryptophan-Reply
Authors: Henry W. Lahmeyer
Journal: JAMA (1990)

<h3>In Reply.—</h3> Dr Burdick and associates report they recently have seen five cases of the eosinophilia-myalgia syndrome. The Centers for Disease Control report (as of February 23, 1990) a total of 1321 case reports.<sup>1</sup>They are unaware of any new cases with onset after December 1989. The dates of onset of Dr Burdick's cases are not noted, although they apparently occurred before January 1990. This problem clearly qualifies as an epidemic, currently of unknown etiology. It is unlikely to be due to tryptophan use alone because millions of people have ingested tryptophan in various forms with no significant ill effects. Even though the syndrome resembles toxic-oil syndrome, no contaminants of tryptophan have been found.<sup>2</sup> When I submitted my comments to<i>JAMA</i>regarding the use of tryptophan in insomnia, there were no reports of ill effects, and the few patients I knew of who were using it were having
Evaluation of Levodopa for Parkinsonism
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Current Comment
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cytomegalovirus Retinitis
Authors: MARK B. MOELLER
Journal: Annals of Internal Medicine (1981)

Letters and Corrections1 March 1981Cytomegalovirus RetinitisMARK B. MOELLER, M.D., JOHN D. HAMILTON, M.D.MARK B. MOELLER, M.D.Search for more papers by this author, JOHN D. HAMILTON, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-94-3-414_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: With their review of cytomegalovirus (CMV) retinitis, Pollard and associates have made a significant contribution (1). Their 14 new cases represent a 45% increase in the number of cases appearing in the literature. Their description of spontaneous healing with no residual evidence of disease broadens the spectrum of a disease previously characterized by progressive retinitis culminating in permanent deficits in visual acuity. Furthermore, their use of adenine arabinoside to treat CMV retinitis is the largest experience reported to date.The authors are to be congratulated for their contribution to our knowledge of CMV retinitis; however, critical examination...References1. POLLARDEGBERTGALLAGHERMERIGAN RPJT. Cytomegalovirus retinitis in immunosuppressed hosts: I. Natural history and effects of treatment with adenine arabinoside. Ann Intern Med. 1980;93:655-64. LinkGoogle Scholar2. CH'IENCANNONWHITLEY LNR. Effect of adenine arabinoside on cytomegalovirus infections. J Infect Dis. 1974;130:32-9. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Duke University Medical Center Durham, NC 27710 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByA Case of Atopic Dermatitis Successfully Treated with Daiseiryuto 1 March 1981Volume 94, Issue 3Page: 414-414KeywordsAdenineCytomegalovirus infectionRetinitisVisual acuity Issue Published: 1 March 1981 PDF DownloadLoading ...
Missed Chances to Prevent Cancer
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effects of inhaled acids on lung biochemistry.
Authors: J A Last
Journal: Environmental Health Perspectives (1989)

Effects of respirable aerosols of sulfuric acid, ammonium sulfate, sodium sulfite, and ammonium persulfate on lungs of rats are reviewed. The literature regarding interactions between ozone or nitrogen dioxide and acidic aerosols (ammonium sulfate, sulfuric acid) is discussed. An unexpected interaction between nitrogen dioxide and sodium chloride aerosol is also discussed. An attempt is made to identify bases for prediction of how and when acid aerosols might potentiate effects of inhaled gases.
Dihydroergotamine-heparin prophylaxis of postoperative deep vein thrombosis
Authors: Mason G. Robertson
Journal: JAMA (1985)

<h3>To the Editor.—</h3> The question not asked in the multicenter trial study<sup>1</sup>is, who does not need dihydroergotamine and heparin prophylaxis against DVT during major surgery? Nor is the question raised by Jack Hirsh<sup>2</sup>in his editorial in the same issue. The study, of course, asked the question, "Does this prophylaxis work?" The answer was in the affirmative. Yet, my question is not unimportant. Many will conclude from this study that<i>all</i>patients older than 40 years undergoing major surgery, barring a contraindication, should have this prophylaxis. They would fall into the category of followers of the American Hippocrates, Dr Benjamin Rush, who did not believe in<i>vis medicatrix naturae</i>but that the wise physician<i>always</i>interceded and left nothing to nature or to chance.<sup>3</sup>Others might consider that of the overall 880 patients studied, subtracting all of those in whom DVT developed in the placebo and
Anesthesiology
Authors: L. J. Saidman
Journal: JAMA (1995)

An increasingly important role for the anesthesiologist is pain management, which, broadly defined, includes treatment of acute postsurgical pain, chronic nonsurgical pain, and cancer-related pain. In response to the need for a cadre of individuals expert in pain management, the American Board of Anesthesiology in 1993 began awarding a Certificate of Added Qualifications in pain management to board-certified anesthesiologists who fulfilled credentialing requirements and who passed a written examination. The principal entrance requirement is completion of a year of formal training in pain management, although, until 1998, a 2-year practice equivalent could be substituted for the training requirement. Through the end of 1994, a total of 834 candidates have been awarded the Certificate of Added Qualifications in pain management. Sophisticated and large studies reflecting an interest in perioperative risk factors and relationships include an assessment of factors related to perioperative nerve injury. The cause of this complication, which has long
777. Targeted Gene Addition into a Putative Safe-Harbor Locus in the Human Genome Using Engineered Zinc Finger Nucleases Russell C. DeKelver, Erica A. Moehle, Jeffrey C. Miller, Jeremy M. Rock, David E. Paschon, Igor Rupniewski, Phillip Y. Tam, Edward J. Rebar, Michael C. Holmes, Philip D. Gregory, Fyodor D. Urnov.
Journal: Molecular Therapy (2007)
Bodies Politic: Diseases, Death and Doctors in Britain, 1650-1900
Authors: R. Carter
Journal: Journal of the Royal Society of Medicine (2002)

Bodies Politic: Diseases, Death and Doctors in Britain, 1650±1900How do you picture history?Conventional visual images from the past portray their subjects in an ostensibly realistic manner, but others convey more personal messages from the artist.Such messages may be coded, or transmitted with brutal directness.Individual people, events and places are transformed into stereotypes and metaphors to provide comment on more general social or political situations, usually with strong overtones of parody, protest or subversion.The subjects are to varying degrees remodelled to form caricatures, which range from the comical to the repulsive.Such images are often supplementary to or indeed directly linked with verbal images in the novels, plays, poems and pamphlets of the times and, to this extent, the visual and the verbal cannot be separated.Both provide valuable commentary on the historical contexts in which they are set.Bodies Politic 1 is one of a new series entitled `Picturing History', and British medicine between 1650 and 1900 provides abundant material for Professor Roy Porter to develop several questionsÐnotably, `How did the body and healing practices . . .supply metaphoric commentary upon the wider world of politics and the body politic?'.The emphasis inevitably falls on `the long eighteenth century', on metropolitan rather than provincial practice, and on patients `of the better sort' with time and money at their disposal.Views of the body itself were inherently con¯icting during this periodÐloathsome object or divine handiwork?Thus Gibbon disliked `. . . the naked frankness of Montaigne who exposes all his malady and the operation of each dose of physic on his nerves and bowels', and he was painfully distressed by his own last and unpleasant illnessÐ `varnish the business for the ladies'.Gibbon's less fastidious contemporaries were, however, deeply interested in other people's bodily misfortunes.Publicity was guaranteed for giants, dwarfs and the malformed, and visits to `the Poore lunatiques' at Bethlem hospital provided (according to taste) edi®cation or raucous sport up until 1770.Mary Toft from Godalming, who claimed to give birth to litters of rabbits, was displayed in London in 1726, and was recorded by Hogarth.Rare but profound enjoyment was to be had from botched executions, and the case of Ann Green, hanged in Oxford in 1650, was widely reported.Anthony a Á Wood recorded that `she was carried away to be anatomized by
N2O exhaust from cryosurgical units may affect physician performance
Authors: E. R. Gonzalez
Journal: JAMA (1979)

Cryosurgicalprobes that employ nitrous oxide (N<sub>2</sub>O) may be hazardous, particularly to physicians working in treatment rooms with suboptimal ventilation and air recirculation. A temporary decrement in psychomotor performance is, at present, the worst hazard, according to the Emergency Care Research Institute (ECRI) of Plymouth Meeting, Pa. Evidence from prior studies indicates that persons exposed to more than 50 ppm of N<sub>2</sub>O may suffer compromised motor and audiovisual skills, diminished dexterity, impaired cognition, and other neurological deficits. The ECRI is a 15-year-old independent, nonprofit, medical device testing corporation. The solution is to scavenge the unit and vent the exhaust outdoors, but this is a measure more easily urged than implemented at present. Although manufacturers have responded favorably to ECRI's finding that N<sub>2</sub>O concentrations in three physicians' offices vastly exceeded the 25-ppm time-weighted average exposure recommended by the National Institute of Occupational Safety and Health, many
The Relation of Pathology to Practice
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Letter: The drug lag
Authors: Edward D. Freis
Journal: JAMA (1976)

<h3>To the Editor.—</h3> After more than a year's delay, Dr Crout, the Director of the Bureau of Drugs of the Food and Drug Administration (FDA) has responded (234:480, 1975) to my editorial (229:689, 1974) on the "drug lag" in introducing new antihypertensive agents in the United States. My editorial was in reference to an article in the same issue ofThe Journal(229:693,1974) by Dr William O'Brien, a British physician who was writing on the treatment of hypertension. Among other drugs, Dr O'Brien advocated the use of bethanidine, debrisoquine, and propranolol, which are either not available or do not have labeling approved to recommend use in hypertension in this country. The expressed purpose of Dr Crout's letter was to correct alleged inaccuracies in the editorial, including my criticism of the delay by the FDA in approving these drugs. My actual statement was as follows: "Applications for approval of these drugs
Abstracts
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Assessment of noninvasive markers in identifying patients at risk in the Brugada syndrome: Insight into risk stratification Takanori Ikeda, Harumizu Sakurada, Koichi Sakabe, Takao Sakata, Mitsuaki Takami, Mahito Noro, Ayaka Kawase, Kenta Kumagai, Naoki Tezuka, Takeshi Nakae, Yoshihisa Enjoji, Tamotsu Tejima, Kaoru Sugi, Tetsu Yamaguchi. Toho University Ohashi Hospital, Tokyo, Japan, Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan
Journal: Journal of the American College of Cardiology (2001)
Comparison of Short-Term Estrogenicity Tests for Identification of Hormone-Disrupting Chemicals
Authors: Helle Raun Andersen, Anna-Maria Andersson, Steven F. Arnold, Herman Autrup, Marianne Barfoed, Nicola A. Beresford, Poul Bjerregaard, Lisette B. Christiansen, Birgitte Gissel, Rene Hummel, Eva Bonefeld Jorgensen, Bodil Korsgaard, Remy Le Guevel, Henrik Leffers, John McLachlan, Anette Moller, Jesper Bo Nielsen, Nicolas Olea, Anita Oles-Karasko, Farzad Pakdel, Knud L. Pedersen, Pilar Perez, Niels Erik Skakkeboek, Carlos Sonnenschein, Ana M. Soto, John P. Sumpter, Susan M. Thorpe, Philippe Grandjean
Journal: Environmental Health Perspectives (1999)

The aim of this study was to compare results obtained by eight different short-term assays of estrogenlike actions of chemicals conducted in 10 different laboratories in five countries.Twenty chemicals were selected to represent direct-acting estrogens, compounds with estrogenic metabolites, estrogenic antagonists, and a known cytotoxic agent.Also included in the test panel were 1 7,Bestradiol as a positive control and ethanol as solvent control.The test compounds were coded before distribution.Test methods included direct binding to the estrogen receptor (ER), proliferation of MCF-7 cells, transient reporter gene expression in MCF-7 cells, reporter gene expression in yeast strains stably transfected with the human ER and an estrogen-responsive reporter gene, and vitellogenin production in juvenile rainbow trout.17p-Estradiol, 177a-ethynyl estradiol, and diethylstilbestrol induced a strong estrogenic response in all test systems.Colchicine caused cytotoxicity only.Bisphenol A induced an estrogenic response in all assays.The results obtained for the remaining test compounds-tamoxifen, ICI 182.780, testosterone, bisphenol A dimethacrylate, 4-n-octylphenol, 4-n-nonylphenol, nonylphenol dodecylethoxylate, butylbenzylphthalate, dibutylphthalate, methoxychlor, o,p'-DDT, p,p'-DDE, endosulfan, chlomequat chloride, and ethanol-varied among the assays.The results demonstrate that careful standardization is necessary to obtain a reasonable degree of reproducibility.Also, similar methods vary in their sensitivity to estrogenic compounds.Thus, short-term tests are useful for screening purposes, but the methods must be further validated by additional interlaboratory and interassay comparisons to document the reliability of the methods.